P3 Health Partners sees FY25 revenue $1.35B-$1.5B, consensus $1.52B

Sees FY25 adjusted EBITDA loss $35M to gain of $5M. “The execution of our previously announced $130+ million EBITDA growth initiatives is going as planned, most of which have been actioned and implemented. Given our progress, we are targeting to be profitable in 2025. Additionally, we have highly supportive shareholders and the contemplated financing will provide adequate liquidity to fund expected working capital needs,” said Aric Coffman, CEO of P3. “Our business model remains fundamentally strong as we continue to drive value for our PCP partners, payors, and patients. We intend to issue full 2025 guidance at the time when we report our fourth quarter 2024 earnings results.”